Spinal Concepts
This article was originally published in The Gray Sheet
Executive Summary
Spinal implant developer raises $9.3 mil. in sale of Series D preferred stock. Proceeds will be used to expand the Austin, Texas firm's sales force, fund ongoing clinical trials of the Infix interbody fusion device, and for R&D projects including gene therapy products for the spine. The privately held firm has raised over $21 mil. since its inception in June 1996